NLS Pharmaceutics secures US$2m equity funding and signs US$25m equity facility to support merger with Kadimastem (Israel) to combine expertise in aiming to become a leader in regenerative medicine in neurodegenerative disorders.
Zürich, 31 March 2025 –
Dewpoint Therapeutics Inc and Mitsubishi Tanabe Pharma Corporation have formed a collaboration, valued at up to $480m, to develop a novel small molecule condensate modulator for ALS, leveraging groundbreaking European research in condensate biology.
AviadoBio Ltd has cashed in €30m upfront and €20m as an equity investment from Astellas Pharma Inc for signing a licence option agreement for its Phase I/II gene therapy programme AVR-01.
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Spanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment.
University of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.
123rf.com/guniita
Dewpoint Therapeutics Inc
Astellas Pharma Inc